-
Spain's PM calls snap election after housing bill defeat
-
N.Irish court hears challenge to disputed Orangemen parade
-
STARCARES Equips Seven Foster Homes for Children and Young People in Tanzania
-
Talking points from the Bahrain Grand Prix in Malaysia
-
Alleged Indian leader of neo-Nazi child abuse ring goes on trial in Paris
-
Yemen, Saudi Arabia target Houthis in new campaign as war escalates
-
Euro, French stocks slide on France debt concerns
-
US-German trio wins medicine Nobel for work on optogenetics
-
Alcaraz advances to Japan Open final
-
Swiatek, Zheng survive three-set tests in China Open third round
-
US-German trio win medicine Nobel for work on optogenetics
-
Hasan says Test cricket momentum turning for Bangladesh
-
Hundreds of French high schools shut as protests persist
-
Intense heat puts births in jeopardy, UN tells Fiji talks
-
Spain PM calls early election after housing crisis defeat
-
US arrests woman accused of spying for China on Taiwan leader's family
-
Stocks rally as 'Goldilocks' jobs data ease rate fears
-
Yemen military announces broad strikes against Houthis
-
Myanmar says 10,000 migrants returned from Malaysia this year
-
Zuckerberg skewered again on screen in 'The Social Reckoning'
-
Big guns back for Australia's Rugby League World Cup defence
-
Fiji urges 'just' climate transition, financing at pre-COP gathering
-
Braves rock Dodgers to level series, Brewers win thriller
-
Thailand's Jeeno overcomes late wobble to win Lotte Championship
-
Most Asia stocks rally as 'Goldilocks' jobs data ease rate fears
-
Brazil heads to run-off as Bolsonaro pulls off shock first place finish over Lula
-
Sunken Silk Road city reveals Central Asia's lost history
-
EU, China to hold Beijing talks to avert trade war
-
Three years on, Israeli rescuer cannot escape October 7
-
Bolsonaro edges past Lula as nail-biter Brazil vote goes to a run-off
-
Research into weight-loss drugs tipped for Nobel as award week opens
-
Rubio visits Iceland as US boosts Arctic presence
-
US Supreme Court hears bid to shut the door on climate suits
-
Bolsonaro leads Lula as nail-biter Brazil vote goes to a run-off
-
Chourio walk-off single lifts Brewers over Padres
-
Patriots inflict first Bills defeat as Chiefs keep winning
-
PREMS Biomedical AI Advances AI-Enhanced Smart Sleeve for Neuromuscular Rehabilitation
-
GameSquare to Present at Upcoming Investor Conferences
-
Chervon Appoints Neil Harrison to the Position of VP Sales, Marketing and MD for Chervon Canada
-
Behind on Back Taxes? Clear Start Tax Explains the IRS Program Thousands Are Using to Cut What They Owe
-
Chervon Names Claudio Chiappetta Vice President of Retail Sales for Chervon Canada
-
Yanmar America Finance Selects Vero Technologies to Support the Launch of Its Captive Floorplan Finance Program
-
Chervon Names Peter J. Carlson Director of Sales for Strategic Accounts
-
TRWD Signs First U.S. Licensing Agreement, Accelerating Recurring Revenue Expansion and 100+ Venue Strategy
-
Peer To Peer Network Launches PTOP Intelligence Lab Website Featuring MOBICARD(TM) and Synaptic Quant(TM)
-
Hypha Labs Targets Disruptive Mushroom Active Ingredient Production
-
Chervon Names Daniel L. Abbott Director of Sales - Western U.S.A.
-
Housekeeping Starts with Branding: Vicapsys Life Sciences Adopts New Corporate Identity Developed by FutureBrand for Vicapsys and Its Stateline Subsidiary
-
Tectonic Metals Appoints Eduard Epshtein as CFO, Bolstering Executive Team for Next Stage of Growth
-
Securitas Technology Releases 2027 Global Technology Outlook Report
Hypha Labs Targets Disruptive Mushroom Active Ingredient Production
Eight-Day Cycles and Potential 80% Cost Savings
LAS VEGAS, NV / ACCESS Newswire / October 5, 2026 / The global functional mushroom market is estimated to reach $42.27 billion in 2026 and projected to grow to $95.95 billion by 2033, according to Grand View Research. Hypha Labs, Inc. is developing a disruptive biomanufacturing platform to address a critical challenge within this expanding industry: producing mushroom-derived active ingredients faster, more consistently, and at lower cost.
Hypha Labs' Mushroom Accelerator™ platform is designed to produce mushroom-derived biological material in approximately eight days, compared with the approximately 90-day conventional cultivation benchmark described by the company. Its developing commercial platform targets potential operational and production cost savings of up to 80% through automation, reduced labor requirements, a smaller production footprint, and minimized biological waste.
The platform's proprietary Micropearls™ provide biological starting material for downstream extraction and formulation of mushroom-derived active ingredients used in nutraceuticals, supplements, functional beverages, and research applications. Controlled bioreactor production is designed to improve batch consistency and make downstream processing more predictable.
Hypha Labs' collaboration with Mycology Resources combines its production technology with mushroom genetics, analytical capabilities, and extraction expertise to support commercial scale-up. The objective is a repeatable supply platform for manufacturers seeking consistent mushroom-derived ingredients.
By combining accelerated production with substantial potential cost reductions, Hypha Labs aims to change the economics of mushroom active ingredient manufacturing.
About Hypha Labs, Inc.
Hypha Labs, Inc. (OTCQB:FUNI) is developing proprietary automated mushroom production technologies designed to improve scalability, consistency, and manufacturing efficiency for the rapidly growing functional mushroom industry.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially due to risks and uncertainties described in the Company's filings with the U.S. Securities and Exchange Commission. The Company undertakes no obligation to update forward-looking statements except as required by law.
From time to time, the Company may post new material information on its website or through its social media profiles at the links below:
LN: https://www.linkedin.com/company/hypha-labs-inc/
FB: https://www.facebook.com/hyphalabs
IG: https://www.instagram.com/hyphalabsinc/
Twitter: https://x.com/Hypha_Labs
For more information about Hypha Labs visit
www.HyphaLabs.com
For the Company's current Investor Presentation please visit
www.HyphaLabs.com/deck
Contact
Hypha Labs, Inc.
702 744 0640
[email protected]
SOURCE: Hypha Labs, Inc.
View the original press release on ACCESS Newswire
G.Stevens--AMWN